Abstract

Case Report

Fatal Immune Checkpoint Inhibitor-associated Myocarditis Mimicking Infiltrative Cardiomyopathy in a 54-year-old Woman with Metastatic Melanoma

Hichem Sakhi*, Virgile Chevance, Laurette Kalifa, Riad Arana, Ariane Laparra, Guillaume Reverdito, Fares Ben Salem, Charles Pottier, Olivier Lambotte, Arshid Azarine* and Sondes Smaali

Published: 04 June, 2024 | Volume 8 - Issue 1 | Pages: 046-050

Introduction: Immune checkpoint inhibitors (ICI) have significantly improved cancer treatment outcomes, but cardiovascular complications such as ICI-associated myocarditis are a major concern. Diagnosing myocarditis requires integrating biomarkers, electrocardiogram (EKG), cardiac imaging, and endomyocardial biopsy. We present a case illustrating these diagnostic challenges, involving a female patient treated with pembrolizumab who developed fatal acute myocarditis mimicking infiltrative cardiomyopathy.
Case report: A 54-year-old woman with mucosal melanoma, treated with pembrolizumab, was hospitalized in May 2023 due to dyspnea and elevated troponin levels. Initial cardiac workups were normal, but subsequent tests revealed borderline cardiac magnetic resonance imaging findings. In late May 2023, the patient was admitted with worsening dyspnea, elevated NT-pro-BNP, and severe hyperlactatemia. Imaging and endomyocardial biopsy confirmed acute myocarditis with atypical presentation, mimicking infiltrative cardiomyopathy. Despite aggressive immunosuppressive therapy, the patient’s condition deteriorated, resulting in cardiogenic shock and death seven days post-admission.
Conclusion: This case underscores the diagnostic and management challenges of ICI-associated myocarditis, particularly with atypical presentations. It highlights the need for vigilant, comprehensive monitoring and further research to improve diagnostic and therapeutic strategies for managing these severe side effects in patients undergoing ICI therapy.

Read Full Article HTML DOI: 10.29328/journal.jro.1001063 Cite this Article Read Full Article PDF

Keywords:

Myocarditis; Cardio-oncology; Infiltrative cardiomyopathy; Cardiac magnetic resonance; Immune checkpoint inhibitors

References

  1. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018 Sep;19(9):e447-e458. doi: 10.1016/S1470-2045(18)30457-1. PMID: 30191849.
  2. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O'Byrne K, Kulasinghe A. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022 Apr 24;29(5):3044-3060. doi: 10.3390/curroncol29050247. PMID: 35621637; PMCID: PMC9139602.
  3. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018 Dec;19(12):1579-1589. doi: 10.1016/S1470-2045(18)30608-9. Epub 2018 Nov 12. PMID: 30442497; PMCID: PMC6287923.
  4. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244. Erratum in: Eur Heart J. 2023 May 7;44(18):1621. PMID: 36017568.
  5. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176. doi: 10.1016/j.jacc.2018.09.072. PMID: 30545455.
  6. Chabior A, Tymińska A, Pawlak A, Giordani A, Caforio A, Grabowski M, Ozierański K. Advances in myocarditis management in the light of the latest research and recent guidelines of the European Society of Cardiology. Cardiol J. 2024;31(2):342-351. doi: 10.5603/cj.95175. Epub 2024 Jan 22. PMID: 38247433; PMCID: PMC11076022.
  7. Sharrack N, Poenar AM, Simms AD, Greenwood JP, Plein S. Acute Myocarditis Mimicking Hypertrophic Cardiomyopathy in Marfan Syndrome and Morphologically Abnormal Mitral Valve. JACC Case Rep. 2022 Jan 19;4(2):105-110. doi: 10.1016/j.jaccas.2021.11.023. PMID: 35106495; PMCID: PMC8784724.
  8. Hiramitsu S, Morimoto S, Kato S, Uemura A, Ohtsuki M, Kato Y, Sugiura A, Miyagishima K, Mori N, Yoda R, Mori K, Iwase M, Hishida H. Significance of transient left ventricular wall thickening in acute lymphocytic myocarditis. Heart Vessels. 2007 Jan;22(1):25-9. doi: 10.1007/s00380-006-0933-1. Epub 2007 Jan 26. PMID: 17285442.
  9. Hauser AM, Gordon S, Cieszkowski J, Timmis GC. Severe transient left ventricular "hypertrophy" occurring during acute myocarditis. Chest. 1983 Feb;83(2):275-7. doi: 10.1378/chest.83.2.275. PMID: 6217952.
  10. Dimarco A, Mansoubi H, Tanner M. An unusual cause of left ventricular hypertrophy. Eur Heart J. 2016 Feb 1;37(5):497. doi: 10.1093/eurheartj/ehv530. Epub 2015 Oct 22. PMID: 26494864.
  11. Coffin ST, Benton SM Jr, Lenihan DJ, Naftilan AJ, Mendes LA. Eosinophilic myocarditis-an unusual cause of left ventricular hypertrophy. Am J Med Sci. 2015 Apr;349(4):358-62. doi: 10.1097/MAJ.0000000000000344. PMID: 25325192.
  12. Liu S, Zheng L, Shen L, Wu L, Yao Y. Clinical Identification and Characteristic Analysis of Giant Cell Myocarditis in 12 Cases. Front Cardiovasc Med. 2021 Apr 13;8:649094. doi: 10.3389/fcvm.2021.649094. PMID: 33928134; PMCID: PMC8076517.
  13. Dahiya DS, Wani F, Guidi JC, Kichloo A. Gastrointestinal Adverse Effects of Immunotherapeutic Agents: A Systematic Review. Gastroenterology Res. 2020 Dec;13(6):227-232. doi: 10.14740/gr1340. Epub 2020 Dec 23. PMID: 33447301; PMCID: PMC7781271.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?